Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Prognostic models in the myeloproliferative neoplasms.

Blood reviews - 1 Jul 2020

Grinfeld Jacob

Abstract excerpt

The management of myelofibrosis (MF) is predominantly supportive, with the use of JAK2 inhibitors or allogeneic stem cell transplantation reserved for patients predicted to have poor overall survival. Identification of these patients is aided by a number of prognostic scoring systems, foremost among them the Dynamic International Prognostic Scoring System (DIPSS). Similarly, the use of cytoreductive therapies in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cytogenetic Analysis
Share to Disease Management
Share to Models, Biological

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Myeloproliferative Disorders

Share to Prognosis

Source

Identifiers

PMID: 32532453
DOI: 10.1016/j.blre.2020.100713

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Prognostic models in the myeloproliferative neoplasms.PMID 32532453Read ↗

Prognostic risk model for patients with high-risk polycythemia vera and essential thrombocythemia.Semantic proximity Read ↗

Distinct clinico-molecular arterial and venous thrombosis scores for myeloproliferative neoplasms risk stratification.Semantic proximity Read ↗

Prognostication in MF: from CBC to cytogenetics to molecular markers.Semantic proximity Read ↗

Molecular biomarkers of thrombosis in myeloproliferative neoplasms.Semantic proximity Read ↗

Genetic Risk Assessment in Myeloproliferative Neoplasms.Semantic proximity Read ↗

Increased risk of thrombosis in JAK2 V617F-positive patients with primary myelofibrosis and interaction of the mutation with the IPSS scoreSemantic proximity Read ↗

Diagnosis, risk stratification, and response evaluation in classical myeloproliferative neoplasms.Semantic proximity Read ↗

Thrombosis-Driven Disease Progression in JAK2-Mutant Polycythemia Vera and Essential Thrombocythemia: Reassessing Risk-Based Management.Semantic proximity Read ↗

Polycythemia vera and essential thrombocythemia: 2017 update on diagnosis, risk-stratification, and management.Semantic proximity Read ↗

The new WHO classification for essential thrombocythemia calls for revision of available evidences.Semantic proximity Read ↗

Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management.Semantic proximity Read ↗

A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.